Association of weight gain and metabolic syndrome in patient taking Clozapine: a 8-year cohort study 
Background
Metabolic syndrome is an important side effect associated with clozapine. It has been hypothesized that weight gain contributes to the development of metabolic syndrome, but a direct diabetogenetic effect has also been suggested. We conducted an 8-year cohort study to determine the association between weight gain and metabolic parameters among schizophrenic patients on clozapine.
Materials and methods
The subjects were hospitalized schizophrenic patients who began to receive clozapine and subsequently had monthly body weight monitoring during the entire study period. Chart reviews were conducted to obtain gender, age at initiation of clozapine treatment, baseline Body Mass Index (BMI), BMI changes after the initiation of clozapine treatment, treatment duration with clozapine and concomitant psychotropic medications. Anthropometric and biochemical measurements were performed to determine the presence of metabolic syndrome.
Results
Patients were maintained on clozapine for an average treatment duration of 56.0 ± 27.8 (range 5 to 96) months. The prevalence of metabolic syndrome was 28.7%. The cohort regression models showed that baseline BMI (p < 0.0001) and BMI change after clozapine treatment (p < 0.0001) were significant factors for metabolic syndrome as were most metabolic parameters except hyperglycemia and diabetes mellitus, which were related to treatment duration (p < 0.05).
Conclusions
For patients treated with clozapine, metabolic syndrome and most metabolic parameters were related to weight gain; however, glucose dysregulation was associated with treatment duration independent of weight gain. The results confirm that monitoring body weight is important, but periodic monitoring of blood sugar may also be required for clozapine patients who do not have significant weight gain.
